142 related articles for article (PubMed ID: 29108005)
1. Identification of genes and critical control proteins associated with inflammatory breast cancer using network controllability.
Wakai R; Ishitsuka M; Kishimoto T; Ochiai T; Nacher JC
PLoS One; 2017; 12(11):e0186353. PubMed ID: 29108005
[TBL] [Abstract][Full Text] [Related]
2. Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer.
Remo A; Simeone I; Pancione M; Parcesepe P; Finetti P; Cerulo L; Bensmail H; Birnbaum D; Van Laere SJ; Colantuoni V; Bonetti F; Bertucci F; Manfrin E; Ceccarelli M
J Transl Med; 2015 May; 13():138. PubMed ID: 25928084
[TBL] [Abstract][Full Text] [Related]
3. Genomic and expression analysis of microdissected inflammatory breast cancer.
Woodward WA; Krishnamurthy S; Yamauchi H; El-Zein R; Ogura D; Kitadai E; Niwa S; Cristofanilli M; Vermeulen P; Dirix L; Viens P; van Laere S; Bertucci F; Reuben JM; Ueno NT
Breast Cancer Res Treat; 2013 Apr; 138(3):761-72. PubMed ID: 23568481
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.
Bertucci F; Ueno NT; Finetti P; Vermeulen P; Lucci A; Robertson FM; Marsan M; Iwamoto T; Krishnamurthy S; Masuda H; Van Dam P; Woodward WA; Cristofanilli M; Reuben JM; Dirix L; Viens P; Symmans WF; Birnbaum D; Van Laere SJ
Ann Oncol; 2014 Feb; 25(2):358-65. PubMed ID: 24299959
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity.
Rypens C; Marsan M; Van Berckelaer C; Billiet C; Melis K; Lopez SP; van Dam P; Devi GR; Finetti P; Ueno NT; Bertucci F; Dirix P; Neven P; Vermeulen P; Dirix L; Van Laere SJ
Breast Cancer Res Treat; 2020 Apr; 180(2):385-395. PubMed ID: 32043194
[TBL] [Abstract][Full Text] [Related]
6. Macrophages Enhance Migration in Inflammatory Breast Cancer Cells via RhoC GTPase Signaling.
Allen SG; Chen YC; Madden JM; Fournier CL; Altemus MA; Hiziroglu AB; Cheng YH; Wu ZF; Bao L; Yates JA; Yoon E; Merajver SD
Sci Rep; 2016 Dec; 6():39190. PubMed ID: 27991524
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Characterization of Immune Cell Infiltration Characteristics and Drug Sensitivity Analysis in Inflammatory Breast Cancer Based on Bioinformatic Strategy.
Zhang Z; Wu H; Shen C; Zhou F
Biochem Genet; 2024 Apr; 62(2):1021-1039. PubMed ID: 37517031
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
[TBL] [Abstract][Full Text] [Related]
9. Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype.
Funakoshi Y; Wang Y; Semba T; Masuda H; Hout D; Ueno NT; Wang X
PLoS One; 2019; 14(9):e0222336. PubMed ID: 31532791
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling of inflammatory breast cancer: a review.
Bertucci F; Finetti P; Vermeulen P; Van Dam P; Dirix L; Birnbaum D; Viens P; Van Laere S
Breast; 2014 Oct; 23(5):538-45. PubMed ID: 24998451
[TBL] [Abstract][Full Text] [Related]
11. High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes.
Bekhouche I; Finetti P; Adelaïde J; Ferrari A; Tarpin C; Charafe-Jauffret E; Charpin C; Houvenaeghel G; Jacquemier J; Bidaut G; Birnbaum D; Viens P; Chaffanet M; Bertucci F
PLoS One; 2011 Feb; 6(2):e16950. PubMed ID: 21339811
[TBL] [Abstract][Full Text] [Related]
12. Systematically identify key genes in inflammatory and non-inflammatory breast cancer.
Chai F; Liang Y; Zhang F; Wang M; Zhong L; Jiang J
Gene; 2016 Jan; 575(2 Pt 3):600-14. PubMed ID: 26403314
[TBL] [Abstract][Full Text] [Related]
13. miRNome of inflammatory breast cancer.
Maltseva DV; Galatenko VV; Samatov TR; Zhikrivetskaya SO; Khaustova NA; Nechaev IN; Shkurnikov MU; Lebedev AE; Mityakina IA; Kaprin AD; Schumacher U; Tonevitsky AG
BMC Res Notes; 2014 Dec; 7():871. PubMed ID: 25471792
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies.
Arora J; Sauer SJ; Tarpley M; Vermeulen P; Rypens C; Van Laere S; Williams KP; Devi GR; Dewhirst MW
Oncotarget; 2017 Apr; 8(16):25848-25863. PubMed ID: 28460441
[TBL] [Abstract][Full Text] [Related]
15. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.
Van Laere SJ; Ueno NT; Finetti P; Vermeulen P; Lucci A; Robertson FM; Marsan M; Iwamoto T; Krishnamurthy S; Masuda H; van Dam P; Woodward WA; Viens P; Cristofanilli M; Birnbaum D; Dirix L; Reuben JM; Bertucci F
Clin Cancer Res; 2013 Sep; 19(17):4685-96. PubMed ID: 23396049
[TBL] [Abstract][Full Text] [Related]
16. Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers.
Li X; Kumar S; Harmanci A; Li S; Kitchen RR; Zhang Y; Wali VB; Reddy SM; Woodward WA; Reuben JM; Rozowsky J; Hatzis C; Ueno NT; Krishnamurthy S; Pusztai L; Gerstein M
Genome Med; 2021 Apr; 13(1):70. PubMed ID: 33902690
[TBL] [Abstract][Full Text] [Related]
17. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.
Van Laere S; Beissbarth T; Van der Auwera I; Van den Eynden G; Trinh XB; Elst H; Van Hummelen P; van Dam P; Van Marck E; Vermeulen P; Dirix L
Clin Cancer Res; 2008 Nov; 14(22):7452-60. PubMed ID: 19010862
[TBL] [Abstract][Full Text] [Related]
18. Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer.
Reddy JP; Atkinson RL; Larson R; Burks JK; Smith D; Debeb BG; Ruffell B; Creighton CJ; Bambhroliya A; Reuben JM; Van Laere SJ; Krishnamurthy S; Symmans WF; Brewster AM; Woodward WA
Breast Cancer Res Treat; 2018 Sep; 171(2):283-293. PubMed ID: 29858753
[TBL] [Abstract][Full Text] [Related]
19. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
[TBL] [Abstract][Full Text] [Related]
20. Gene set analysis of post-lactational mammary gland involution gene signatures in inflammatory and triple-negative breast cancer.
Bambhroliya A; Van Wyhe RD; Kumar S; Debeb BG; Reddy JP; Van Laere S; El-Zein R; Rao A; Woodward WA
PLoS One; 2018; 13(4):e0192689. PubMed ID: 29617367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
